Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 18/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427142 | 1.00 | NOTUM (0.42) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL10387512 | 0.80 | PIK3CD (0.35) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL20836150 | 0.80 | NOTUM (0.42) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL18328550 | 0.80 | TRPV4 (0.34) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL31194141 | 0.80 | NOTUM (0.42) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL7933949 | 0.80 | NOTUM (0.41) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL10354992 | 0.79 | AXL (0.33) | AXLPRKCI | |
| SCHEMBL6971788 | 0.78 | NOTUM (0.39) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL1034691 | 0.78 | NOS3 (0.39) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 | |
| SCHEMBL17506246 | 0.78 | NOTUM (0.39) | NOTUMCYP1A2CYP2C9CHRNB2CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998050362-A1 | PREPARATION OF 2,5-DICHLORO-(3-TRIFLUOROMETHYL)PYRIDINE | DOW AGROSCIENCES LLC (US) | 1998-11-12 | — | — | WO | claimed |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12565483-B2 | Oxopyrrolidine urea FPR2 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-03 | — | — | US | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| EP-4541422-A2 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | Gilead Sciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3873884-B1 | 3-(QUINOLIN-8-YL)-1,4-DIHYDROPYRIDO[3,4-D]PYRIMIDIN-2,4-DIONE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GILEAD SCIENCES INC (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2010130423-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130422-A1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130424-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130424-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2205096-A2 | FUNGICIDAL COMPOSITION AND METHOD FOR CONTROLLING NOXIOUS FUNGI | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009060734-A2 | FUNGICIDAL COMPOSITION AND METHOD FOR CONTROLLING NOXIOUS FUNGI | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-05-14 | — | — | WO | disclosed |
| EP-1296952-A1 | BENZOYLPYRIDINE DERIVATIVE OR ITS SALT, FUNGICIDE CONTAINING IT AS AN ACTIVE INGREDIENT, ITS PRODUCTION PROCESS AND INTERMEDIATE FOR PRODUCING IT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002002527-A1 | BENZOYLPYRIDINE DERIVATIVE OR ITS SALT, FUNGICIDE CONTAINING IT AS AN ACTIVE INGREDIENT, ITS PRODUCTION PROCESS AND INTERMEDIATE FOR PRODUCING IT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2002-01-10 | — | — | WO | disclosed |
| WO-1998050362-A1 | PREPARATION OF 2,5-DICHLORO-(3-TRIFLUOROMETHYL)PYRIDINE | DOW AGROSCIENCES LLC (US) | 1998-11-12 | — | — | WO | disclosed |
| US-4266064-A | CATALYTIC FLUORINATION IN A VAPOR PHASE | ISHIHARA SANGYO KAISHA LTD. (JP) | 1981-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565483-B2 | Oxopyrrolidine urea FPR2 agonists | FPR1, FPR2, FPR3 | NOTUM 4592/4885CYP1A2 2397/4885CYP2C9 2905/4885 |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | NOTUM 603/4885CYP1A2 118/4885CYP2C9 175/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | NOTUM 355/4885CYP1A2 180/4885CYP2C9 158/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | NOTUM 2455/4885CYP1A2 212/4885CYP2C9 306/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | NOTUM 3808/4885CYP1A2 4181/4885CYP2C9 3544/4885 |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | NOTUM 3721/4885CYP1A2 185/4885CYP2C9 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.